Oncology Drug Approval - Accelerated

Bridging the gap between biomarkers and In Vitro Companion Diagnostics

Technologies & Platforms

At MolecularMD we use the best tools for the job because we know how important it is to accelerate the approval and commercialization of your therapies. Our solutions are designed to support all phases of your oncology drug development process as well as to adapt rapidly to any changes in your strategies.

And by remaining platform agnostic, we are able to select the most appropriate technology and platform to establish the desired specifications for our assays and meet all your criteria. Some of our latest assays have been developed employing exciting new technologies such as droplet digital PCR (ddPCR) and next-generation sequencing (NGS).

Method

Platform

Biomarker Assay

ddPCR

Bio-Rad QX100™/QX200™

Copy Number | Gene Expression | Mutations

Immunohistochemistry

Ventana Benchmark XT

Protein Expression

Multiplex

nanoString nCounter®

Copy Number | Gene Expression

Next Generation Sequencing

Illumina MiSeq

Ion PGM™ System

Copy Number | Mutations | RNA Fusions

RT-qPCR

Applied Biosystems 7500 & QuantStudio™

Bio-Rad CFX96™

Qiagen Rotor-Gene Q

Mutations | Gene Expression

Sanger Sequencing

Applied Biosystems 3730xl DNA Analyzer

Mutations

MolecularMD discusses the clinical application of liquid biopsy or circulating tumor DNA (ctDNA) and its benefits within the field of oncology and companion diagnostics.